Bacterin Announces Second Quarter 2013 Results
Bacterin Announces Second Quarter 2013 Results
- Revenue increased to $8.3 million from $8.2 million reported during the second quarter of 2012
- Revenues for the period, excluding distributor stocking orders, increased 13% over the first quarter of 2013
- Revenues for the six month period ended June 30, 2013 increased 6% year over year to approximately $16.9 million
- The Company closed an equity financing in June 2013 which resulted in net proceeds of approximately $4.5 million to the Company.
BELGRADE, Mt.--(BUSINESS WIRE)-- Bacterin International Holdings, Inc. (NYSE MKT: BONE), a leader in the development of revolutionary bone graft material and coatings for medical applications, today reported its financial results for the second quarter ended June 30, 2013. The Company reported revenues of approximately $8.3 million and a net loss for the second quarter of approximately $2.5 million, or ($0.05) per common share, compared to a net income of approximately $730,000, or $0.02 per common share, reported during the same period in 2012.
The Company also reported revenues of approximately $16.9 million and a net loss of approximately $4.2 million, or ($0.09) per common share, over the first six months of 2013. This compares to revenues of approximately $16.0 million and a net loss of approximately $316,000, or ($0.01) per common share, over the same period in 2012.
Revenue for the second quarter was approximately $8.3 million, compared to approximately $8.2 million for the same period during 2012. The increase was primarily attributed to higher volume sales, which were partially offset by lower sales prices resulting from discounting associated with higher volume distributors and preferred vendors. For the first six months of 2013, revenues were approximately $16.9 million compared to approximately $16.0 million for the same period of 2012.
"Despite the challenges we incurred during the second quarter of 2013 associated with the resignation of our prior CEO, this was a satisfying quarter," said John Gandolfo, co-interim CEO and Chief Financial Officer of Bacterin International Holdings. "We were able to keep our senior management team intact, which has resulted in winning back previous accounts and stabilizing our core hospital business. As a result of our efforts, we realized a sequential increase in our core hospital business during the period over the first quarter of 2013. We are currently assessing sales strategies which will enhance the sustained growth of our core business during the second half of the year. There is a continuing opportunity to leverage new sales channels and we are well positioned to increase our market presence.
For the second quarter of 2013, gross profit was approximately $4.7 million, a decrease of 20% from $5.9 million in the second quarter of 2012. Gross margin for the period was 57%, which compares to a gross margin of 72% reported for the same period last year. During the quarter, the Company took a charge of approximately $500,000 associated with the write off of expired products primarily related to an improvement being made to our hMatrix manufacturing process which we expect to result in an improved product in the future. Excluding this charge, gross margins in the quarter would have been 63%.The first six months of 2013 saw gross profit of $10.2 million, compared to $11.8 million for the same period of 2012. Gross margins for the first six months were 60% in 2013 compared to 74% in 2012.
Sales and Marketing Expenses
Sales and marketing expenses for the second quarter increased to $4.2 million as compared to $3.8 million for the same period during 2012. As a percentage of revenues, selling and marketing expenses increased to 51%, which compares to 47% reported for the second quarter of 2012. The increase was primarily the result of higher personnel costs incurred prior to the recent reduction of headcount and increased administrative fees for GPO Contracts initiated during the third quarter of 2012. In addition, we incurred $103,000 of severance costs associated with headcount reductions announced during the second quarter of 2013.
The first six months of 2013, sales and marketing expenses remained flat at $8.0 million compared to the prior year.
General and Administrative Expenses
In the second quarter, general and administrative expenses (G&A) remained unchanged at $2.3 million for the period as compared to the same period last year. The second quarter 2013 figure included $164,000 of severance costs associated with the previously announced headcount reduction program as well as $124,000 of non-recurring expenses associated with a legal settlement. As a percentage of revenues, general and administrative expenses were 27% in 2013 as compared to 28% for the second of quarter 2012.
The first six months experienced a slight increase of general and administrative expenses to $5.1 million, which compares with $4.9 million reported during the second quarter of 2012. As a percentage of revenues, G&A was 30% in the first half of 2013 compared to 31% in 2012.
The Company defines earnings before interest, taxes, depreciation and amortization ("EBITDA") as net income/loss from operations before depreciation, amortization and non-cash stock-based compensation. EBITDA for the second quarter of 2013 was a loss of $1.4 million, compared to breakeven EBITDA for the second quarter of 2012. Excluding the write-off of expired inventory of approximately $500,000 and severance expenses associated with the headcount reduction of $267,000, the second quarter 2013 EBITDA loss was $637,000. See "GAAP to non-GAAP Reconciliation" below for further information on this non-GAAP measure.
Cash and cash equivalents were $5.1 million and net accounts receivable were $6.2 million on June 30, 2013, compared to cash and cash equivalents of $4.9 million and net accounts receivable of $7.2 million on December 31, 2012.
Kent Swanson, Chairman of Bacterin International Holdings added, "The sequential growth of our recurring revenues is a clear indication of the success we are having with our base hospital business. Now with our recent clearance from the FDA to market the OsteoSelect DBM Putty for spinal fusion procedures, we are well positioned to leverage our products and execute on our sales strategies to further penetrate the marketplace and grow this business."
Conference Call Details
Management will hold a conference call to discuss its financial results at 10:00 a.m. ET, on Wednesday, August 7, 2013. Please refer to the information below for conference call dial-in information and webcast registration.
Please call the conference telephone number 5-10 minutes prior to the start time. An operator will register your name and organization. If you have any difficulty connecting with the conference call, please contact the Cockrell Group at 1-877-889-1972.
|Bacterin's Second Quarter and Six Month 2013 Results Call|
Following the live call, a replay will be available on the Company's website, www.bacterin.com, under "Investor Info".
About the Presentation of EBITDA
EBITDA is not a financial measure calculated and presented in accordance with U.S. generally accepted accounting principles (GAAP) and should not be considered as an alternative to net income, operating income or any other financial measures so calculated and presented, nor as an alternative to cash flow from operating activities as a measure of liquidity. The company defines EBITDA as net income/(loss) from operations before depreciation, amortization and non-cash stock-based compensation. Other companies (including competitors) may define EBITDA differently. The company presents EBITDA because management believes it to be an important supplemental measure of performance that is commonly used by securities analysts, investors and other interested parties in the evaluation of companies in our industry. Management also uses this information internally for forecasting and budgeting. It may not be indicative of the historical operating results of Bacterin nor is it intended to be predictive of potential future results. Investors should not consider EBITDA in isolation or as a substitute for analysis of the company's results as reported under GAAP. See "GAAP to non-GAAP Reconciliation" below for further information on this non-GAAP measure.
About Bacterin International Holdings
Bacterin International Holdings, Inc. (NYSE MKT: BONE) develops, manufactures and markets biologics products to domestic and international markets. Bacterin's proprietary methods optimize the growth factors in human allografts to promote bone growth, subchondral repair and dermal growth. These products are used in a variety of applications including enhancing fusion in spine surgery, relief of back pain, promotion of bone growth in foot and ankle surgery, promotion of cranial healing following neurosurgery and subchondral repair in knee and other joint surgeries.
Bacterin's Medical Device division develops and licenses coatings for various medical device applications. For further information, please visit www.bacterin.com.
Important Cautions Regarding Forward-looking Statements
This news release contains certain disclosures that may be deemed forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to significant risks and uncertainties. Forward-looking statements include statements that are predictive in nature, that depend upon or refer to future events or conditions, or that include words such as "continue," "efforts," "expects," "anticipates," "intends," "plans," "believes," "estimates," "projects," "forecasts," "strategy," "will," "goal," "target," "prospects," "potential," "optimistic," "confident," "likely," "probable" or similar expressions or the negative thereof. Statements of historical fact also may be deemed to be forward-looking statements. We caution that these statements by their nature involve risks and uncertainties, and actual results may differ materially depending on a variety of important factors, including, among others: the Company's ability to meet its existing and anticipated contractual obligations, including financial covenant and other obligations contained in the Company's secured lending facility; the Company's ability to manage cash flow and achieve profitability; the Company's ability to develop, market, sell and distribute desirable applications, products and services and to protect its intellectual property; the ability of the Company's sales force to achieve expected results; the ability of the Company's customers to pay and the timeliness of such payments; the Company's ability to obtain financing as and when needed; changes in consumer demands and preferences; the Company's ability to attract and retain management and employees with appropriate skills and expertise; the Company's ability to attract and retain a well qualified Chief Executive Officer; the Company's ability to successfully conclude government investigations; the impact of changes in market, legal and regulatory conditions and in the applicable business environment, including actions of competitors; and other factors. Additional risk factors are listed in the Company's Annual Report on Form 10-K and Quarterly Report on Form 10-Q under the heading "Risk Factors." The Company undertakes no obligation to release publicly any revisions to any forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events, except as required by law.
|BACTERIN INTERNATIONAL HOLDINGS, INC.|
|CONDENSED CONSOLIDATED BALANCE SHEETS|
|June 30,||As of|
|Cash and cash equivalents||$||5,135,974||$||4,926,066|
|Trade accounts receivable, net of allowance for doubtful accounts of $518,419 and $1,576,955, respectively||6,226,619||7,154,065|
|Prepaid and other current assets||667,871||353,271|
|Total current assets||25,833,527||25,574,823|
|Property and equipment, net||5,458,272||5,234,867|
|Intangible assets, net||564,693||592,378|
|LIABILITIES & STOCKHOLDERS' EQUITY|
|Accounts payable - related party||478,762||418,922|
|Warrant derivative liability||1,374,044||984,356|
|Current portion of capital lease obligations||160,267||149,729|
|Current portion of royalty liability||804,250||698,408|
|Current portion of long-term debt||46,320||45,135|
|Total current liabilities||9,500,701||8,694,429|
|Capital lease obligation, less current portion||162,880||245,703|
|Long term royalty liability, less current portion||6,677,474||6,839,935|
|Long-term debt, less current portion||15,342,246||14,483,102|
|Commitments and Contingencies|
|Preferred stock, $.000001 par value; 5,000,000 shares authorized; no shares issued and|
Common stock, $.000001 par value; 95,000,000 shares authorized; 51,528,544 shares issued and outstanding as of June 30, 2013 and 42,877,770 shares issued and outstanding as of December 31, 2012
|Additional paid-in capital||55,253,597||51,897,890|
|Total Stockholders' Equity||3,435,752||4,232,385|
|Total Liabilities & Stockholders' Equity||$||35,119,053||$||34,495,554|
|BACTERIN INTERNATIONAL HOLDINGS, INC.|
|CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS|
|Three months ended June 30,||Six months ended June 30,|
|Royalties and other||70,294||94,667||165,753||193,719|
|Cost of tissue and medical devices sales||3,572,674||2,329,432||6,693,360||4,188,154|
|General and administrative||2,256,287||2,319,851||5,113,369||4,910,623|
|Sales and marketing||4,205,333||3,835,209||8,003,710||7,981,552|
|Depreciation and amortization||100,470||95,206||206,848||214,280|
|Non-cash consulting expense||(932)||(24,069)||(31,229)||304,184|
|Total Operating Expenses||6,561,158||6,226,197||13,292,698||13,410,639|
|Loss from Operations||(1,866,984)||(347,357)||(3,100,403)||(1,620,520)|
|Other Income (Expense)|
|Change in warrant derivative liability||460,270||1,301,576||1,095,625||1,519,127|
|Total Other Income (Expense)||(616,107)||1,077,874||(1,051,946)||1,304,242|
|Net Loss Before (Provision) Benefit for Income Taxes||(2,483,091)||730,517||(4,152,349)||(316,278)|
|(Provision) Benefit for Income Taxes|